The physicians, nurses, and other healthcare providers who treat PLGD patients are essential to our mission of improving patients’ experiences and outcomes. This section contains information and links to help healthcare professionals most effectively treat PLGD patients. Please also consider signing up for our newsletter to stay up-to-date on the latest research, treatments, and clinical trials available for PLGD patients.
Ryplazim CME for Healthcare Providers
Hope on the Horizon for Patients with Plasminogen Deficiency Type 1, a 1-hour CME-eligible activity, by Dr. Amy Shapiro, with funding from Postgraduate Institute for Medicine and Spire Learning, and an educational grant from Kedrion Biopharma. *CME credit will be available until Feb 8, 2024.
Diagnosis: Plasminogen Antigen/Activity and Genetic Testing
Diagnostic Checklist PDF
PLGD is diagnosed with a blood test measuring plasminogen activity and antigen levels. Not all laboratories perform plasminogen activity and antigen tests needed for an accurate diagnosis. We are aware that Esoterix as a national laboratory has the capability to perform both of these tests accurately. Other laboratories may be capable as well. We recommend that the laboratory utilized is confirmed as capable and accurate.
Currently, genetic testing is being performed primarily as part of study participation. Subjects participating in the HISTORY study (see Research) are having their genetic testing done at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center in Milan, Italy.
Management: Optimize Ryplazim Dosing
WAPPS-Hemo Plasminogen pK Model
Activating the Plasminogen pK Model
Now available, a population pK model describing the pK of Ryplazim to help with dosing for individual patients
What to do with a Newly Diagnosed Patient
Ensure your patient has a medical home at a Hemophilia Treatment Center (HTC)
PLGD can manifest in many different ways, including most commonly ophthalmologic lesions and gum lesions, but it is important to remember that this is a systemic disorder, requiring whole body monitoring for lesion development. A Hemophilia Treatment Center has the resources to be a medical home for PLGD patients, with physicians who can conduct thorough physical exams, and support staff to assist patients with the many challenges this diagnosis can bring, such as assistance navigating insurance, educating patients to perform home infusions, and support for school / work disruptions or needs. And, HTCs are uniquely equipped to collect and input valuable clinical data about PLGD so that we can continue to learn the best way to manage this rare disorder. Help your patient find the nearest HTC here so they can have the most comprehensive care available.
Request Ryplazim for your plasminogen deficiency patient
- For US patients: Healthcare providers can to complete the the “Patient Enrollment Form” under the Ordering RYPLAZIM section of the Ryplazim website. We encourage HCPs seeking additional information or guidance on how to complete the Enrollment Form/New Start Form to contact a Rare Disease Specialist by using this form.
- For non-US patients: Kedrion is unable to provide commercial product outside the United States, as Ryplazim is currently only approved in the US. However, for patients with serious or life-threatening conditions, HCPs may reach out to our Global Medical and Scientific Service at MedInfo@kedrion.com .
Refer your patient to ongoing research studies
Currently, the Hypoplasminogenemia: An International RetroSpecTive and PrOspective CohoRt StudY (HISTORY) study is enrolling patients to follow them over time and learn more about the natural history of PLGD. Patients can learn more and decide if they would like to enroll by following this link.
More Information
- OMIM Reference
- Rare Coagulation Disorders Research Room
- Hypoplasminogenemia: An International RetroSpecTive and PrOspective CohoRt StudY (HISTORY)
- NIH Genetic and Rare Diseases (GARD) Information Center
- OrphaNet Portal for Rare Diseases